Pharmaceutical monoclonal antibodies: Production, guidelines to cell engineering and applications

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 2, 2013, Pages 13-20

  Chandel, Pankaj ^a   Harikumar, S L ^a  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

Author keywords

Application of mAbs; Cell engineering; Expression system; Expression vector; Human mAbs; Hybridoma cell production; Monoclonal antibody; Transfection methods; Vector design

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; GEMTUZUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; POLYCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; CANCER THERAPY; CELL ENGINEERING; CELL SELECTION; ELECTROPORATION; EXPRESSION VECTOR; GENE EXPRESSION SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; GLYCOSYLATION; HUMAN; MARKER GENE; METABOLIC ENGINEERING; NONHUMAN; PROTEIN PROCESSING; PURIFICATION; REVIEW; STABLE TRANSFECTION; SUSPENSION;

EID: 84875912632     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Cambrosio A, Keating P. Between fact and technique: the beginnings of hybridoma technology. Journal of the History of Biology 1992; 25 (2): 175-230.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495-497.
3. Vlasek J, Ionescu R. Hetergeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods. Current Pharmaceutical Biotechnology 2008; 9 (6): 468-481.
4. McCafferty J, Griffiths A, Winter G, Chiswell D. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348 (6301): 552-554.
5. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-129.
6. Rang HP. Pharmacology. Edinburgh: Churchill Livingstone. 2003.
7. Pharmaceutical Technology. PhRMA Reports Identifies More than 400 Biotech Drugs in Development. August 24, 2006. Retrieved 2006-09-04.
8. Takimoto CH, Calvo E. Principles of Oncologic Pharmacotherapy in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) [http://www.cancernetwork.com/cancer-management-11/ Cancer Mana.
9. Nilsang S, Nandakumar KS, Galaev IY, Rakshit SK, Holmdahl R, Mattiasson B, Kumar A. Monoclonal antibody production using a new supermacroporous cryogel bioreactor, Biotechnol. Prog. 2007; 23, 932-939.
10. Jain E, Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol. Adv. 26, 46-71.
11. Lloyd DR, Al-Rubeai M, Cell cycle, in: MC. Flickinger MC., Drew SW. Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, John Wiley and Sons. New York; (1999) (Eds.), 465-476.
12. Ozturk SS, Hu WS. Cell Culture Technology for Pharmaceutical and Cell based Therapies. CRC Press New York. 2006
13. Werner RG, Noe W, Kopp K, Schluter M. Appropriate mammalian expression systems for biopharmaceuticals. Drug Res. 1998; 48, 870-880.
14. Jordan M, Kohne C, Wurm FM. Transfection and protein expression in mammalian cells. Cytotechnology. 1998, 26, 39-47.
15. Ozdemir O. The construction of a mammalian transfection vector for expression of cytosine-5 specific DNA methyltransferase gene M. Msp1 in cultured cells. Turk. J. Biol. 1998; 22,161-170.
16. Blaas L, Musteanu M, Eferl R, Bauer A, Casanova E. Bacterial artificial chromosomes improve recombinant protein production in mammalian cells. BMC Biotechnol. 2009; 9, 3.
17. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotech. 2004; 22, 1393-1398.
18. Edelman GM, Meech R, Owens GC, Jones FS. Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. Proc. Natl. Acad. Sci. USA. 2000; 97, 3038-3043.
19. Yuansheng Y, Mariati Ho SCL, Yap MGP. Mutated polyadenylation signals for controlling expression levels of multiple genes in mammalian cells. Biotechnol. Bioeng. 2009; 102, 1152-1160.
20. Lonza GS. Gene Expression System. . 2009
21. Melton DW, Ketchen AM, Kind AJ, McEwan C, Paisley D, Selfridge J. A one-step gene amplification system for use in cultured mammalian cells and transgenic animals. Transgenic Res. 2001; 10, 133-142.
22. Batard P, Jordan M, Wurm F, Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection. Gene. 2001; 270, 61-68.
23. Chenuet S, Martinet D, Besuchet N-Schmutz, Wicht M, Jaccard N, Bon AC et al. Calcium phosphate transfection generates mammalian recombinant cell lines with higherspecific productivity than polyfection. Biotechnol. Bioeng. 101 (2008) 937-945.
24. Tait AS, Brown CJ, Galbraith DJ, Hines MJ, Hoare M, Birch JR et al. Transient production of recombinant proteins by Chinese hamster ovary cells using polyethyleneimine/DNA complexes in combination with microtubule disrupting anti-mitotic agents. Biotechnol. Bioeng. 2004; 88, 707-721.
25. Bohm E, Voglauer R, Steinfellner W, Kunert R, Borth N, Katinger H. Screening for improved cell performance: selection of subclones with altered production kinetics or improved stability by cell sorting. Biotechnol. Bioeng. 2004; 88, 699-706.
26. Choi SS, Rhee WJ, Park TH. Beneficial effect of silkworm hemolymph on a CHO cell system: inhibition of apoptosis and increase of EPO production. Biotechnol. Bioeng. 2005, 91, 793-800.
27. Yoon SK, Song JK, Lee GM. Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol. Bioeng. 2003; 82, 289-298.
28. Hendrick V, Winnepenninckx P, Abdelkafi C, Vandeputte O, Cherlet M, Marique T, et al. Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis. Cytotechnology. 2001; 36, 71-83.
29. Ku SCY, Ng DTW, Yap MGS, Chao SH. Effects of over expression of X-box binding protein 1 on recombinant protein production in Chinese hamster ovary and NS0 myeloma cells. Biotechnol. Bioeng. 2008; 99, 155-164.
30. Davies J, Jiang LY, Pan LZ, LaBarre MU, Andersen D, Reff M. Expression of GnTIII in recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcyRIII. Biotechnol. Bioeng. 2001; 74, 288-294.
31. Yamane-Ohnuki N, Kinoshita S, Miho IU, Kusunoki M, Iida S, Nakano R, Wakitani M, et al. Establishment of FUT 8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 2004; 87, 614-622.
32. Savelkoul HFJ, Vossen ACTM, Breedland AG, Tibbe GJM. Semipreparative purification and validation of monoclonal antibodies for immunotherapy in mice. J. Immunol. Methods. 1994; 172, 33-42.
33. Keen MJ, Rapson NT. Development of a serum-free culture medium for the large scale production of recombinant protein from a Chinese hamster ovary cell line. Cytotechnology. 1995; 17, 153-163.
34. Lee GM, Kim EJ, Kim NS, Yoon SK, Ahn YH, Song JY. Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design. J. Biotechnol. 1999; 69, 85-93
35. Butler M, Huzel N, Barnabe N. Unsaturated fatty acids enhance cell yields and perturb the energy metabolism of an antibody-secreting hybridoma. Biochem. J. 1997; 322, 615-623.
36. Jing Yang, Quing Yi. Therapeutic monoclonal antibodies for multiple myeloma; an update and future prospective. Am J blood Res. 2011; 1, 22-23.
37. Pande Katre Deepshikha, Bala kumud, Kharakwal Harsha. RNA based therapeutics. Int J Pharm Pharm Sci. 2012; 4 (3), 1-11.
38. Kumar Shobhit, Kumar Gupta Satish, Kumar Sharma Pramod. Recent developments in targeted drug delivery system for crossing blood brain barrier; A review. Int J Pharm Pharm Sci. 2012; 4 (2), 36-41.